Pei He

Pei He

Stanford University - Stanford / United States
Medical and Health Sciences / Biostatistics
AD Scientific Index ID: 1650854
person_outline Pei He's MOST POPULAR ARTICLES
1-) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialA Rittmeyer, F Barlesi, D Waterkamp, K Park, F Ciardiello, J Von Pawel, ...The Lancet 389 (10066), 255-265, 201737912017
2-) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialL Fehrenbacher, A Spira, M Ballinger, M Kowanetz, J Vansteenkiste, ...The Lancet 387 (10030), 1837-1846, 201624282016
3-) Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated …L Fehrenbacher, J von Pawel, K Park, A Rittmeyer, DR Gandara, SP Aix, ...Journal of thoracic oncology 13 (8), 1156-1170, 20182592018
4-) Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic …M Peeters, KS Oliner, TJ Price, A Cervantes, AF Sobrero, M Ducreux, ...Clinical Cancer Research 21 (24), 5469-5479, 20152172015
5-) Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK studyDR Gandara, J von Pawel, J Mazieres, R Sullivan, Å Helland, JY Han, ...Journal of Thoracic Oncology 13 (12), 1906-1918, 2018147*2018